Ontology type: schema:ScholarlyArticle Open Access: True
2018-12
AUTHORSIrina Proskorovsky, Agnes Benedict, Sylvie Negrier, Danielle Bargo, Rickard Sandin, Krishnan Ramaswamy, Jigar Desai, Joseph C. Cappelleri, James Larkin
ABSTRACTBACKGROUND: In the absence of head-to-head trials comparing axitinib with cabozantinib or everolimus, the aim of this study was to conduct an indirect comparison of their relative efficacy in patients with metastatic renal cell carcinoma (mRCC), using data from the AXIS and METEOR trials. METHODS: Progression-free survival (PFS) and overall survival (OS) in prior sunitinib-treated patients with mRCC were compared by conducting matching-adjusted indirect comparison (MAIC) analyses, including base-case and sensitivity analyses. Individual patient-level data from prior sunitinib-treated patients who received axitinib in AXIS were weighted to match published baseline characteristics of prior sunitinib-treated patients who received either cabozantinib or everolimus in METEOR. RESULTS: There was no statistically significant difference in PFS (aHR [adjusted hazard ratio] = 1.15 [CI: 0.82-1.63]) and OS (aHR = 1.00 [CI: 0.69-1.46]) between axitinib versus cabozantinib in the base-case analysis. In the sensitivity analysis, PFS (aHR = 1.39 [CI: 1.00-1.92]) and OS (aHR = 1.35 [CI: 0.95-1.92]) were shorter for axitinib compared with cabozantinib; however, the OS difference was not statistically significant. Axitinib was associated with significantly longer PFS compared with everolimus in the base-case (aHR = 0.53 [CI: 0.36-0.80]) and sensitivity analyses (aHR = 0.63 [CI: 0.45-0.88]), respectively. Results suggested an OS benefit for axitinib versus everolimus in base-case analyses (aHR = 0.63 [CI: 0.42-0.96]); however, the difference in OS in the sensitivity analysis was not statistically significant (aHR = 0.84 [CI: 0.59-1.18]). CONCLUSIONS: MAIC analyses suggest PFS and OS for axitinib and cabozantinib are dependent on the Memorial Sloan Kettering Cancer Center definition used; in the base-case analysis, there was no significant difference in PFS and OS between axitinib and cabozantinib. In the sensitivity analysis, PFS in favour of cabozantinib was significant; however, the trend for prolonged OS with cabozantinib was not significant. For axitinib and everolimus, MAIC analyses indicate patients treated with axitinib may have an improved PFS and OS benefit when compared to everolimus. Disparities between the base-case and sensitivity analyses in this study underscore the importance of adjusting for the differences in baseline characteristics and that naïve indirect comparisons are not appropriate. More... »
PAGES1271
http://scigraph.springernature.com/pub.10.1186/s12885-018-5157-0
DOIhttp://dx.doi.org/10.1186/s12885-018-5157-0
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1110759467
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/30567533
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Anilides",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Axitinib",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Carcinoma, Renal Cell",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Disease-Free Survival",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Everolimus",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Progression-Free Survival",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Proportional Hazards Models",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Pyridines",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Sunitinib",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"name": [
"Evidera, 7575 Trans-Canada Highway, Suite 404, H4R 1V6, Montreal, Quebec, Canada"
],
"type": "Organization"
},
"familyName": "Proskorovsky",
"givenName": "Irina",
"id": "sg:person.0723163720.31",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723163720.31"
],
"type": "Person"
},
{
"affiliation": {
"name": [
"Evidera, Budapest, Hungary"
],
"type": "Organization"
},
"familyName": "Benedict",
"givenName": "Agnes",
"id": "sg:person.01067707272.62",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067707272.62"
],
"type": "Person"
},
{
"affiliation": {
"name": [
"University of Lyon, Centre L\u00e9on B\u00e9rard, Lyon, France"
],
"type": "Organization"
},
"familyName": "Negrier",
"givenName": "Sylvie",
"id": "sg:person.0723756046.31",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723756046.31"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Pfizer (United States)",
"id": "https://www.grid.ac/institutes/grid.410513.2",
"name": [
"Pfizer Inc, New York, NY, USA"
],
"type": "Organization"
},
"familyName": "Bargo",
"givenName": "Danielle",
"id": "sg:person.010375770560.48",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010375770560.48"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Pfizer (Sweden)",
"id": "https://www.grid.ac/institutes/grid.420142.1",
"name": [
"Pfizer AB, Vetenskapsv\u00e4gen 10, 191 90, Sollentuna, Sweden"
],
"type": "Organization"
},
"familyName": "Sandin",
"givenName": "Rickard",
"id": "sg:person.0756726716.47",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756726716.47"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Pfizer (United States)",
"id": "https://www.grid.ac/institutes/grid.410513.2",
"name": [
"Pfizer Inc, New York, NY, USA"
],
"type": "Organization"
},
"familyName": "Ramaswamy",
"givenName": "Krishnan",
"id": "sg:person.0600603143.74",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0600603143.74"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Pfizer (United States)",
"id": "https://www.grid.ac/institutes/grid.410513.2",
"name": [
"Pfizer Inc, New York, NY, USA"
],
"type": "Organization"
},
"familyName": "Desai",
"givenName": "Jigar",
"id": "sg:person.01132720503.65",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132720503.65"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Pfizer (United States)",
"id": "https://www.grid.ac/institutes/grid.410513.2",
"name": [
"Pfizer Inc, New York, NY, USA"
],
"type": "Organization"
},
"familyName": "Cappelleri",
"givenName": "Joseph C.",
"id": "sg:person.01340453362.44",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340453362.44"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Royal Marsden NHS Foundation Trust",
"id": "https://www.grid.ac/institutes/grid.5072.0",
"name": [
"Royal Marsden NHS Foundation Trust, London, UK"
],
"type": "Organization"
},
"familyName": "Larkin",
"givenName": "James",
"id": "sg:person.01255356274.07",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255356274.07"
],
"type": "Person"
}
],
"citation": [
{
"id": "https://doi.org/10.1158/1078-0432.ccr-11-0553",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1003173433"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2008.21.4809",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1003290766"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/2162-3619-2-32",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1008593355",
"https://doi.org/10.1186/2162-3619-2-32"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/1471-2288-12-9",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1010370832",
"https://doi.org/10.1186/1471-2288-12-9"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s1470-2045(13)70093-7",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1017252421"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.jval.2012.05.004",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1017355577"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/cncr.25219",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1017587632"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/cncr.25219",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1017587632"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa1510665",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1019970557"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1185/03007995.2016.1140028",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1020375126"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.3111/13696998.2013.768530",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1020783661"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2004.06.132",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1022235480"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.2165/11592490-000000000-00000",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1024355436",
"https://doi.org/10.2165/11592490-000000000-00000"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1185/03007995.2014.977992",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1025383996"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s1470-2045(16)30107-3",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1031150467"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.2147/cer.s97885",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1037697585"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s1470-2045(14)70484-x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1043226190"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s0140-6736(08)61039-9",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1045744105"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.eururo.2007.03.035",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1047653672"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s40263-013-0102-x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1048158014",
"https://doi.org/10.1007/s40263-013-0102-x"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s40263-013-0102-x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1048158014",
"https://doi.org/10.1007/s40263-013-0102-x"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.clinthera.2015.09.013",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1051027115"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s0140-6736(11)61613-9",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1052713041"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1371/journal.pone.0184423",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1091532595"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/s41416-018-0164-0",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1106858927",
"https://doi.org/10.1038/s41416-018-0164-0"
],
"type": "CreativeWork"
}
],
"datePublished": "2018-12",
"datePublishedReg": "2018-12-01",
"description": "BACKGROUND: In the absence of head-to-head trials comparing axitinib with cabozantinib or everolimus, the aim of this study was to conduct an indirect comparison of their relative efficacy in patients with metastatic renal cell carcinoma (mRCC), using data from the AXIS and METEOR trials.\nMETHODS: Progression-free survival (PFS) and overall survival (OS) in prior sunitinib-treated patients with mRCC were compared by conducting matching-adjusted indirect comparison (MAIC) analyses, including base-case and sensitivity analyses. Individual patient-level data from prior sunitinib-treated patients who received axitinib in AXIS were weighted to match published baseline characteristics of prior sunitinib-treated patients who received either cabozantinib or everolimus in METEOR.\nRESULTS: There was no statistically significant difference in PFS (aHR\u2009[adjusted hazard ratio]\u2009=\u20091.15 [CI: 0.82-1.63]) and OS (aHR\u2009=\u20091.00 [CI: 0.69-1.46]) between axitinib versus cabozantinib in the base-case analysis. In the sensitivity analysis, PFS (aHR\u2009=\u20091.39 [CI: 1.00-1.92]) and OS (aHR\u2009=\u20091.35 [CI: 0.95-1.92]) were shorter for axitinib compared with cabozantinib; however, the OS difference was not statistically significant. Axitinib was associated with significantly longer PFS compared with everolimus in the base-case (aHR\u2009=\u20090.53 [CI: 0.36-0.80]) and sensitivity analyses (aHR\u2009=\u20090.63 [CI: 0.45-0.88]), respectively. Results suggested an OS benefit for axitinib versus everolimus in base-case analyses (aHR\u2009=\u20090.63 [CI: 0.42-0.96]); however, the difference in OS in the sensitivity analysis was not statistically significant (aHR\u2009=\u20090.84 [CI: 0.59-1.18]).\nCONCLUSIONS: MAIC analyses suggest PFS and OS for axitinib and cabozantinib are dependent on the Memorial Sloan Kettering Cancer Center definition used; in the base-case analysis, there was no significant difference in PFS and OS between axitinib and cabozantinib. In the sensitivity analysis, PFS in favour of cabozantinib was significant; however, the trend for prolonged OS with cabozantinib was not significant. For axitinib and everolimus, MAIC analyses indicate patients treated with axitinib may have an improved PFS and OS benefit when compared to everolimus. Disparities between the base-case and sensitivity analyses in this study underscore the importance of adjusting for the differences in baseline characteristics and that na\u00efve indirect comparisons are not appropriate.",
"genre": "research_article",
"id": "sg:pub.10.1186/s12885-018-5157-0",
"inLanguage": [
"en"
],
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1024632",
"issn": [
"1471-2407"
],
"name": "BMC Cancer",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "18"
}
],
"name": "Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses",
"pagination": "1271",
"productId": [
{
"name": "readcube_id",
"type": "PropertyValue",
"value": [
"3ef2fb80629bf314a50551c6f0d3bd4837131769f19d8a673511f34415ded062"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"30567533"
]
},
{
"name": "nlm_unique_id",
"type": "PropertyValue",
"value": [
"100967800"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1186/s12885-018-5157-0"
]
},
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1110759467"
]
}
],
"sameAs": [
"https://doi.org/10.1186/s12885-018-5157-0",
"https://app.dimensions.ai/details/publication/pub.1110759467"
],
"sdDataset": "articles",
"sdDatePublished": "2019-04-11T13:20",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000368_0000000368/records_78964_00000001.jsonl",
"type": "ScholarlyArticle",
"url": "https://link.springer.com/10.1186%2Fs12885-018-5157-0"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-5157-0'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-5157-0'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-5157-0'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-5157-0'
This table displays all metadata directly associated to this object as RDF triples.
270 TRIPLES
21 PREDICATES
67 URIs
36 LITERALS
24 BLANK NODES